前列腺癌神经内分泌分化的研究进展  

Neuroendocrine differentiation in prostate cancer: an advance

作　　者：董克勤 张金鹏 王超[1] 孙颖浩[1] DONG Ke-qin;ZHANG Jin-peng;WANG Chao;SUN Ying-hao(Department of Urology,Changhai Hospital,Naval Medical University (Second Military Medical University),Shanghai 200433,China)

机构地区：[1]海军军医大学(第二军医大学)长海医院泌尿外科,上海200433

出　　处：《第二军医大学学报》2019年第2期191-195,共5页Academic Journal of Second Military Medical University

基　　金：上海市"重中之重"泌尿系统疾病临床医学中心项目(2017ZZ01005)~~

摘　　要：神经内分泌性前列腺癌是一种恶性程度极高的前列腺癌亚型,绝大多数神经内分泌性前列腺癌发生于去势抵抗性前列腺癌患者接受抗雄激素治疗之后。这种获得神经内分泌表型的细胞分化过程称为神经内分泌分化,是一种公认的前列腺癌抗雄激素治疗耐药的耐药机制,并且与临床不良预后明确相关。目前对于神经内分泌性前列腺癌的生理病理特征均尚未形成共识,因此针对这一亚型前列腺癌的治疗尤为棘手。本文通过综述与神经内分泌性前列腺癌及前列腺癌神经内分泌分化发生、进展相关的最新研究成果,总结热门靶点,为同行诊治与研究神经内分泌性前列腺癌提供新思路。Neuroendocrine prostate cancer(NEPC)is a highly malignant subtype of prostate cancer and it mostly occurs in castration-resistant prostate cancer patients after antiandrogen therapy.The process of cell differentiation to obtain neuroendocrine phenotypes is called neuroendocrine differentiation(NED).It is a proposed mechanism of prostate cancer resistance to androgen-resistance therapy,which is associated with poor prognosis.At present,there is no consensus on the physiological and pathological characteristics of NEPC,and the treatment of this subtype is particularly difficult.This paper reviews the latest findings related to NEPC and NED,and summarizes the most studied targets,hoping to provide new ideas for peer diagnosis,treatment and research of NEPC.

关 键 词：前列腺肿瘤 神经内分泌瘤 细胞分化 肿瘤抗药性 

分 类 号：R737.25[医药卫生—肿瘤]